Association between gastrointestinal motility and macrophage/mast cell distribution in mice during the healing stage after DSS-induced colitis

MIO KODANI, HIROKAZU FUKUI, TOSHIHIKO TOMITA, TADAYUKI OSHIMA, JIRO WATARI and HIROTO MIWA

Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan

Received November 27, 2017; Accepted April 11, 2018

DOI: 10.3892/mmr.2018.8926

Abstract. Irritable bowel syndrome (IBS) frequently occurs after infectious colitis or inflammatory bowel disease in patients with complete remission. This suggests that post-inflammation-associated factors may serve a role in the pathophysiology of IBS; however, the mechanism responsible remains unclear. In the present study, the involvement of macrophages and mast cells in alteration of gastrointestinal (GI) motility was investigated in mice in the remission stage after acute colitis. C57BL/6 mice were administered 2% dextran sulfate sodium in drinking water for 5 days and their intestinal tissues were investigated at intervals for up to 24 weeks. Expression of the mannose receptor (MR) and tryptase was examined by immunohistochemistry, and the GI transit time (GITT) was measured by administration of carmine red solution. A minimal degree of inflammatory cell infiltration persisted in the colon and also the small intestine of mice in remission after colitis and the GITT was significantly shorter. The number of muscularis MR-positive macrophages was significantly increased in the small intestine of mice in remission after colitis and negatively correlated with GITT. Furthermore, results indicated that the number of muscularis tryptase-positive mast cells was significantly increased throughout the intestine of mice during the healing process after colitis and was positively correlated with GITT. The present findings suggested an increased number of macrophages and/or mast cells in the intestinal muscular layer may be associated with the pathophysiology of GI dysmotility after colitis.

Introduction

Irritable bowel syndrome (IBS) is a type of functional gastrointestinal disorder (FGID) characterized by symptoms such as abdominal pain or discomfort and stool irregularities, unassociated with metabolic or organic abnormalities (1,2). A number of factors are involved in the pathophysiology of IBS, such as visceral sensitivity, gastrointestinal (GI) motility, brain-gut interaction and psychosocial stress (1,2). Interestingly, IBS occurs frequently in patients recovering from infectious colitis, (3,4) and we have reported that IBS-like symptoms are often observed in patients with inflammatory bowel disease (IBD) even after the bowel inflammation has been eliminated (5). In such patients, despite macroscopic healing of the intestinal mucosa, IBS-like symptoms persist. Although it has not been fully clarified how IBS symptoms are manifested after infectious colitis or during remission after IBD, it is tempting to speculate that a minimal degree of inflammation and associated gut immune activation may play a pathophysiological role (3,4,6,7). Among immune cells, mast cell is highlighted in the pathophysiology of IBS since the number of mast cells is increased in the colonic tissues in patients with IBS and moreover correlated with the severity of their clinical symptoms (8,9). In addition, recent evidences have revealed that macrophages play pivotal roles in GI motility via acting on myenteric neural cells, (10-13) and indeed, the infiltration of macrophages in the colonic tissues may be enhanced in IBS patients (9,14). Accordingly, in order to clarify the pathophysiological roles of immune cells, the investigation of mast cells and macrophages in experimental IBS model appears to be important.

Dextran sulfate sodium (DSS)-induced colitis is an animal model used widely to investigate the pathophysiology of various types of human colitis (15). It has been shown that mice treated with DSS for 5-7 days develop severe acute colitis, and then undergo healing of the damaged colonic tissue. However, the pathophysiology and mucosal immune alteration after remission has not been fully studied in this
animal model. Then, to examine whether the mice in remission after DSS-induced colitis are useful as a model for IBS after acute colitis, we have observed those mice in a time-dependent manner. Subsequently, this animal model showed significant alterations of GI motility and immune cell infiltration in the GI tract, being possibly resemble to the subjects with post-inflammatory IBS. In the present study, we therefore investigated the involvement of immune cells, focusing mast cell and macrophage that are highlighted in IBS studies, and analyzed its relation to the alteration of GI motility in mice in remission after acute colitis.

**Materials and methods**

**Animal model.** C57BL/6 mice (8-week-old females) were used in this study. All the mice were maintained in cages on a 12 h light/dark cycle under specific pathogen-free conditions and allowed free access to food and water. The mice were administered 2% DSS (molecular weight 36,000-50,000; ICN Biomedicals Inc, Aorano, OH, USA) in drinking water for five days and sacrificed at various time points thereafter. Their GI tissues were removed, cut open along the longitudinal axis, rinsed with saline, and fixed in neutral aqueous phosphate-buffered 10% formalin for histological examinations. This animal experiment was carried out with the approval of the Animal Use and Care Committee at Hyogo College of Medicine.

**Histological evaluation.** The fixed tissues were embedded in paraffin, cut perpendicularly to the surface at a thickness of 4 µm, and stained with hematoxylin and eosin. The degree of inflammatory cell infiltration in the small intestine and colon was scored on a scale of 0 to 3 as follows: 0, normal; 1, inflammatory cell infiltration into the mucosal layer; 2, up to the submucosal layer; 3, beyond the submucosal layer. The scores were evaluated for all of the slides from the small intestine and colon of each mouse, and the results were averaged.

**Immunohistochemistry.** Immunohistochemical staining for the mannose receptor (MR; a marker of M2-polarized macrophages) and tryptase (a marker of mast cells) was performed using an Envision kit (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) as described previously (16). The primary antibodies applied were: anti-MR (dilution 1:5,000; cat. no. ab64693; Abcam, Cambridge, UK) and anti-tryptase antibody (dilution 1:4,000; cat. no. ab2378; Abcam). The sections were deparaffinized, rehydrated and placed in PBS for MR staining or placed in 1X Dako REAL Target Retrieval Solution (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) followed by microwave treatment for tryptase staining. Then, to quench endogenous peroxidase activity, the sections were pretreated with 0.3% H₂O₂ in methanol for 25 min at room temperature. The sections were washed in PBS and incubated with the primary antibodies at 4°C overnight. Thereafter, the slides were incubated with horseradish peroxidase-conjugated secondary antibodies (ready-to-use; cat. nos. K4001 or K4003; Dako; Agilent Technologies, Inc.) at room temperature for 30 min, visualized using 3,3'-diaminobenzidine tetrahydrochloride with 0.05% H₂O₂ for 3 min, and counterstained with Mayer's hematoxylin. Under a light microscope (Olympus CX41; Olympus Corporation, Tokyo, Japan), MR- and tryptase-positive inflammatory cells were counted in a 200-µm stretch of the entire length of well-oriented tissue sections in at least 4 randomly selected fields from the small intestine to colon of each mouse, and the average was calculated.

**GI transit time (GITT).** GITT was measured as described previously (17). In brief, the mice orally received 0.3 ml of 0.5% methylcellulose solution including 6% carmine red (Wako Pure Chemical Industries, Ltd., Osaka, Japan). They were then allowed access to food and water ad libitum until the first red fecal pellet appeared. GITT was determined as the time period between oral gavage and the appearance of the first red fecal pellet.

**Statistical analysis.** All values were expressed as the mean ± SEM. Significance of differences between two animal groups was analyzed by Mann-Whitney U-test. Correlations among GITT, MR expression and tryptase expression were assessed by linear regression analysis. *P*<0.05 was considered to indicate a statistically significant difference.

**Results**

**Inflammatory cell infiltration in the intestinal tract of mice after DSS-induced colitis.** As shown in Fig. 1, inflammatory cell infiltration in the intestinal tract of mice after DSS-induced colitis was evaluated. Strong infiltration of inflammatory cells was observed in not only the mucosal but also the muscular layer in the colonic tissues of mice in the acute phase of DSS-induced colitis (Fig. 1A). The severity of colonic inflammatory cell infiltration peaked at 2-4 weeks after DSS induction (Fig. 1E). Thereafter, it gradually declined but remained at a very weak level in the resolving phase (Fig. 1E). Thus, although most parts of the colonic mucosa appeared macroscopically normal, a minimal degree of inflammatory cell infiltration was still evident in some parts of colonic tissues in the resolving phase (Fig. 1B).

In the small intestine, weak infiltration of inflammatory cells was microscopically evident in the acute phase of DSS-induced colitis (Fig. 1C), although the macroscopic appearance was normal. Moreover, it was noteworthy that a minimal degree of inflammatory cell infiltration was sustained in some parts of the small intestine in the resolution phase (Fig. 1D and F).

**GITT in mice after DSS-induced colitis.** In normal mice, GITT was prolonged with increasing age (from 8 to 32 weeks) (Fig. 2). At two weeks after the start of the experiment, GITT was shorter in mice with DSS-induced colitis than in normal controls, although the difference was not significant. On the other hand, at four weeks later, GITT was significantly longer in mice with DSS-induced colitis than in normal controls. In contrast, however, GITT again became significantly shorter in mice in the resolution phase (at 24 weeks) of DSS colitis.

**Expression of MR and tryptase in mice after DSS-induced colitis.** We next examined the localization and population of MR-positive macrophages and tryptase-positive mast cells in the small intestine and colon of mice after DSS-induced colitis. In normal mice, MR-positive macrophages were scattered in...
both the mucosal and muscular layers of the colon (Fig. 3). In the distal colon, the number of MR-positive macrophages in the mucosal layer increased with age, whereas it remained very small in the muscular layer (Fig. 4). In mice with DSS-colitis, the number of MR-positive macrophages was significantly increased in the muscular layer throughout the small intestine and colon at 2 weeks after DSS induction (Fig. 4). Furthermore, it was significantly increased in the small-intestinal muscular layer at 24 weeks after DSS induction, and similar findings were observed in the muscular layer of the colon (Figs. 3 and 4).

In normal mice, tryptase expression was detected in the immune cells in the lamina propria but was hardly evident in the muscular layer throughout the small intestine and colon (Fig. 5). In those mice, the number of tryptase-positive cells in the mucosal layer increased with age (Fig. 6). In mice with DSS-colitis, the number of tryptase-positive cells was increased.
significantly greater in not only the mucosal but also the muscular layer in the small intestine or colon between 4 and 12 weeks after DSS induction (Figs. 5 and 6).

GITT and its association with MR or tryptase expression. The correlation between GITT and MR or tryptase expression was evaluated in the experimental mice (DSS-treated and untreated) by linear regression analysis. GITT was negatively correlated with the number of MR-positive cells in the muscular layer of the jejunum (Fig. 7). In terms of tryptase expression, GITT was positively correlated with the number of tryptase-positive cells in the muscular layer of the jejunum and colon (Fig. 8).

Discussion

FGIDs frequently occur in patients after infectious colitis (3,4) although endoscopic examinations reveal no apparent abnormality in the enteric lumen, suggesting that some form of cryptic molecular alteration plays a pathophysiologic role. In this context, it is tempting to speculate that post-inflammation-associated factors are central to the mechanism of FGID development after inflammation (3,4,6,7). Although DSS-induced colitis is a well-established animal model, the associated GI motility has not been examined intensively. In the present study, we investigated GITT in mice with DSS-induced colitis at various time intervals. As shown in Fig. 1, GITT was shortened in the acute phase of DSS-induced colitis, reflecting the fact that diarrhea occurs during this period in this model (15). On the other hand, GITT was conversely prolonged during the healing process from 4 to 12 weeks after DSS induction. Histopathologic examination using microscopy demonstrated mild infiltration of inflammatory cells, implying that alteration of the immune system may affect GI motility. Furthermore, we found that a minimal degree of inflammatory cell infiltration remained in the intestine in the resolution phase after 24 weeks and that GITT became significantly shortened again at this time point. These findings suggest that alteration of the immune system certainly affects GI motility, although further studies of the infiltrating immune cells and the mediators they produce would be warranted.

In the present study, we investigated mice after induction of DSS-colitis focusing on macrophages and mast cells as these have received attention as key players in FGIDs after inflammation (8,10). MR-positive macrophages and tryptase-positive mast cells were observed not only in the mucosal but also the muscular layer of the intestinal tract. Interestingly, at 2 and 24 weeks after DSS-colitis induction, the number of macrophages was increased in the muscular layer of the intestinal tract, and GITT was simultaneously shortened. Moreover, from 4 to 12 weeks after DSS-colitis induction, the number of mast cells was increased, and GITT was prolonged. These finding strongly suggest that macrophages are involved in the acceleration of GI motility whereas mast cells are associated with the suppression of GI motility. Indeed, we showed that GITT was negatively correlated with the number of muscle-associated macrophages and positively correlated with that of mast cells. Although it is difficult to explain how GI motility is affected by these infiltrating immune cells, some alteration in their...
profile may be associated with a change in GI motility during the healing process after acute colitis.

With regard to the involvement of macrophages and mast cells in post-inflammation GI dysfunction, interaction between the enteric nerve system (ENS) and smooth muscle (18,19) is greatly affected by immune cell-producing mediators such as cytokines, chemokines, neuropeptides or proteases (11,20,21). Indeed, mast cells are able to release histamine, serotonin, tryptase and prostaglandins, and those mediators are possible to act on their specific receptors of myenteric neural cells, leading to altered motor function (8). Similarly to mast cells, macrophages are likely to affect ENS and smooth muscles with various mediators (10-13). Interestingly, macrophages have been recently classified into the M1 and M2 type that mainly produce Th1 and Th2 cytokines, respectively (22,23). In detail, M1 macrophages release proinflammatory cytokines such as TNFα, IL-1β and IL-6 and their stimulation acts on ENS and smooth muscle, resulting in the suppression of GI motility (10,12). On the other hand, M2 macrophages may suppress the expression of proinflammatory cytokines in M1 macrophage by release anti-inflammatory cytokines including IL-10, (10,24) possibly resulting in the acceleration of GI motility. In this context, we showed in the present study that M2 macrophage were increased in the muscular layer of the intestinal tract after remission of colitis, supporting the possibility that these may be involved in the acceleration of GI motility observed during the period of colitis remission. On the other hand, not only M2 macrophages but also mast cells are known to infiltrate into the muscle layer in the intestine and may accelerate GI motility through stimulation with Th2 cytokines, histamine or serotonin (8). Therefore, we expected that the increase of muscle-associated mast cells might result in acceleration of GI motility. In humans, mast cells in the colonic mucosa are increased in patients with not only diarrhea but also constipation predominant IBS, (25,26) suggesting that these mast cells may not be a factor in the modification of intestinal movements. Although this study did not obtain any evidence for a mechanical role of muscle-associated mast cells in intestinal motility, the present animal model may be useful for investigating the role of mast cells in post-inflammatory FGIDs.

In summary, we have shown that GI dysmotility occurs in mice that are in remission after colitis, and that histopathologically, there is a significant increase of macrophages and mast cells in the muscular layer of the intestinal tract. Moreover, we have demonstrated that muscle-associated macrophages may be involved in the acceleration of GI motility, whereas
muscle-associated mast cells may be associated with its delay. Together, our findings suggest that the increased number of macrophages and/or mast cells in the intestinal muscular layer plays a pathophysiologic role in post-colitis GI dysmotility.

Acknowledgements
The authors would like to thank Chiyomi Itoh and Mayumi Yamada of Hyogo College of Medicine for their technical assistance.

Funding
This work was supported in part by Grants-in-aid for Scientific Research (grant no.17K09363) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors' contributions
HF conceived a designed research and interpreted results of experiments. TT, TO, JW and HM also contributed to the design of the study and the interpretation of experimental results. MK and HF performed experiments, analyzed data, prepared figures and drafted manuscript. MK, HF, TT, TO, JW and HM approved final version of manuscript. HF, TT, TO, JW and HM edited and revised manuscript.

Ethics approval and consent to participate
This study involved no human data or tissues. The animal experiments were carried out with the approval of the Animal Use and Care Committee at Hyogo College of Medicine.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mozlin F and Spiller RC: Functional bowel disorders. Gastroenterology 130: 1480‑1491, 2006.
2. Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, Niesler B, Quigley EM, Rajilić-Stojanović M, Schemann M, et al.: Irritable bowel syndrome. Nat Rev Gastroenterol Hepatol 9: 48‑58, 2012.
3. DuPont AW: Post‑infectious irritable bowel syndrome. Curr Gastroenterol Rep 9: 378‑384, 2007.
4. Beatty JK, Bhardwaj A and Buret AG: Post‑infectious irritable bowel syndrome: Mechanistic insights into chronic disturbances following enteric infection. World J Gastroenterol 20: 3976‑3985, 2014.
5. Tomita T, Kato Y, Takimoto M, Yamasaki T, Kondo T, Kono T, Tozawa K, Yokoyama Y, Ikehara H, Ohda Y, et al.: Prevalence of irritable bowel syndrome‑like symptoms in Japanese patients with inactive inflammatory bowel disease. J Neurogastroenterol Motil 22: 661‑669, 2016.
6. Törnblom H, Lindberg G, Nyberg B and Veress B: Full‑thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 123: 1972‑1979, 2002.
7. Ford AC and Talley NJ: Mucosal inflammation as a potential etiologica factor in irritable bowel syndrome: A systematic review. J Gastroenterol 46: 421‑431, 2011.
8. Wouters MM, Vicario M and Santos J: The role of mast cells in functional GI disorders. Gut 65: 155‑168, 2016.
9. Barbara G, Cremone C, Carini G, Bellacosa L, Zecchi L, De Giorgi R, Corinaldesi R and Stanghellini V: The immune system in irritable bowel syndrome. J Neurogastroenterol Motil 17: 349‑359, 2011.
10. Cipriani G, Gibbons SJ, Kashyap PC and Farrugia G: Intrinsic gastrointestinal macrophages: Their phenotype and role in gastrointestinal motility. Cell Mol Gastroenterol Hepatol 2: 120‑130.e1, 2016.
11. Shea‑Donohue T, Notari L, Sun R and Zhao A: Mechanisms of smooth muscle responses to inflammation. Neurogastroenterol Motil 24: 802‑811, 2012.
12. Türler A, Schwarz NT, Türler E, Kalf JC and Bauer AJ: MCP‑1 causes leukocyte recruitment and subsequently endotoxemic ileus in rat. Am J Physiol Gastrointest Liver Physiol 282: G145‑G155, 2002.
13. Zhao A, Urban F, Anthony RM, Sun R, Stiltz J, van Rooijen N, Wynn TA, Gause WC and Shea‑Donohue T: Th2 cytokine‑induced alterations in intestinal smooth muscle function depend on alternatively activated macrophages. Gastroenterology 135: 217‑225, 2008.
14. Boyer J, Saint‑Paul MC, Dadone B, Patoureas S, Vivinus MH, Ouvrier D, Michiels JF, Piché T and Tulic MK: Inflammatory cell distribution in colon mucosa as a new tool for diagnosis of irritable bowel syndrome: A promising pilot study. Neurogastroenterol Motil 30, 2018.
15. Chassaign B, Attion JD, Malleshappa M and Vijay‑Kumar M: Dextran sulfate sodium (DSS)‑induced colitis in mice. Curr Protoc Immunol: 104; 25, 2014.
16. Kitayama Y, Fukui H, Hara K, Eda H, Kodani M, Yang M, Sun C, Yamagishi H, Tomita T, Oshima T, et al.: Role of regulating gene i in claudin expression and barrier function in the small intestine. Transl Res 173: 92‑100, 2016.
17. Eda H, Fukui H, Uchiyama R, Kitayama Y, Hara K, Yang M, Kodani M, Tomita T, Oshima T, Watari J, et al.: Effect of Helicobacter pylori infection on the link between GLP‑1 expression and motility of the gastrointestinal tract. PLoS One 12: e0177232, 2017.
18. Mayer EA, Tillisch K and Gupta A: Gut‑brain axis and the microbiota. J Clin Invest 125: 926‑938, 2015.
19. Wood JD: Neuropathophysiology of functional gastrointestinal disorders. World J Gastroenterol 13: 1313‑1332, 2007.
20. Lakhan SE and Kirchgesner A: Neuroinflammation in inflammatory bowel disease. J Neuroinflammation 7: 37, 2010.
21. Yang M, Fukui H, Eda H, Xu X, Kitayama Y, Hara K, Kodani M, Tomita T, Oshima T, Watari J, et al.: Involvement of gut microbiota in association between GLP‑1 receptor expression and gastrointestinal motility. Am J Physiol Gastrointest Liver Physiol 312: G367‑G373, 2017.
22. Canton J, Neculai D and Grinstein S: Scavenger receptors in homeostasis and immunity. Nat Rev Immunol 13: 621‑634, 2013.
23. Novoselov VV, Sazonova MA, Ivanova EA and Orekhov AN: Role of alternatively activated macrophages. Gastroenterology 135: 217‑225, 2008.
24. Boyer J, Saint‑Paul MC, Dadone B, Patoureas S, Vivinus MH, Ouvrier D, Michiels JF, Piché T and Tulic MK: Inflammatory cell distribution in colon mucosa as a new tool for diagnosis of irritable bowel syndrome: A promising pilot study. Neurogastroenterol Motil 30, 2018.
25. Mayer EA, Tillisch K and Gupta A: Gut‑brain axis and the microbiota. J Clin Invest 125: 926‑938, 2015.
26. Wood JD: Neuropathophysiology of functional gastrointestinal disorders. World J Gastroenterol 13: 1313‑1332, 2007.
27. Lakhan SE and Kirchgesner A: Neuroinflammation in inflammatory bowel disease. J Neuroinflammation 7: 37, 2010.
28. Yang M, Fukui H, Eda H, Xu X, Kitayama Y, Hara K, Kodani M, Tomita T, Oshima T, Watari J, et al.: Involvement of gut microbiota in association between GLP‑1 receptor expression and gastrointestinal motility. Am J Physiol Gastrointest Liver Physiol 312: G367‑G373, 2017.
29. Canton J, Neculai D and Grinstein S: Scavenger receptors in homeostasis and immunity. Nat Rev Immunol 13: 621‑634, 2013.
30. Novoselov VV, Sazonova MA, Ivanova EA and Orekhov AN: Role of alternatively activated macrophages. Gastroenterology 135: 217‑225, 2018.
31. Mayer EA, Tillisch K and Gupta A: Gut‑brain axis and the microbiota. J Clin Invest 125: 926‑938, 2015.